Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Inclusion Criteria: * Chronic Myeloid Leukemia in the Chronic Phase. * Patients with BCR-ABL-negative checks. * 15 years old over. * ECOG performance status (PS) score 0-2. * Adequate organ function (hepatic, renal and lung). * Signed written informed consent. Exclusion Criteria: * A case with the double cancer of the activity. * Women who are pregnant or breastfeeding. * Patients with complications or a history of severe. * Patients with mutation of T315I、F317L、V299L. * Patients with additional chromosome abnormalities. * The case of Pleural effusion with poor control. * Patients with a history of hematopoietic stem cell transplantation.